{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-037976","form_type":"8-K","ticker":null,"cik":"0000786947","company_name":"ACURA PHARMACEUTICALS, INC","filed_at":"2025-04-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.264966+00:00","generated_at":"2026-05-23T08:37:59.681695+00:00","sec_items":["1.01","2.01","2.03","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Acura receives $200K in new loans from controlling shareholder; debt due May 31, warns of possible bankruptcy","bullets":["Secured note principal now $7,794,279 with ~$650,000 accrued interest; 5.25% interest rate, due May 31, 2025.","New $100,000 loans from controlling shareholder AD Pharma on April 4 and April 18, 2025; AD Pharma owns ~65% of Acura common stock.","If not paid by May 31, 2025, overdue amounts bear default interest at 7.5% per annum.","Without additional financing by mid-May 2025, Acura warns it may scale back operations, furlough employees, or seek bankruptcy; total loss of shareholder value possible."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-037976","json":"https://secwatch.observer/filing/0001104659-25-037976.json","markdown":"https://secwatch.observer/filing/0001104659-25-037976.md","text":"https://secwatch.observer/filing/0001104659-25-037976.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/786947/000110465925037976/0001104659-25-037976-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/786947/000110465925037976/tm2513007d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T08:37:59.681695+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"524aa7b3eaee42e9cb05866dadeef5499628413c","claim":"ACURA PHARMACEUTICALS, INC incurred loan of loans of $100,000 with Abuse Deterrent Pharma, LLC at 5.25% maturing May 31, 2025.","evidence_excerpt":"On each of April 4, 2025 and April 18, 2025 we received loans of $100,000 from Abuse Deterrent Pharma, LLC (\"AD Pharma\").","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/786947/000110465925037976/0001104659-25-037976-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"loans of $100,000"},{"label":"Counterparty","value":"Abuse Deterrent Pharma, LLC"},{"label":"Rate","value":"5.25%"},{"label":"Maturity","value":"May 31, 2025"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}